Development of a radiolabeled probe for detecting membrane type-1 matrix metalloproteinase on malignant tumors - PubMed (original) (raw)
Development of a radiolabeled probe for detecting membrane type-1 matrix metalloproteinase on malignant tumors
Takashi Temma et al. Biol Pharm Bull. 2009 Jul.
Free article
Abstract
Membrane type-1 matrix metalloproteinase (MT1-MMP) expressed on the tumor cell surface activates pro-MMP-2 and pro-MMP-13 to exacerbate the malignancy, suggesting its suitability as a target molecule for diagnosis by in vivo molecular imaging. Thus, we prepared radiolabeled anti-MT1-MMP monoclonal antibody (mAb) as a novel radiolabeled probe for detecting MT1-MMP in vivo and evaluated its usefulness in breast tumor-bearing rodents. (99m)Tc-anti-MT1-MMP mAb was prepared using HYNIC as a bifunctional chelating agent and immunoreactivity was evaluated by flow cytometry. MT1-MMP expression in breast carcinoma cells (rat: Walker-256 and MRMT-1, mouse: FM3A) was measured by Western blotting. In vivo biodistribution was examined for 48 h using tumor-implanted rodents followed by estimation of radiation absorbed by a standard quantitation platform Organ Level Internal Dose Assessment (OLINDA). (99m)Tc-anti-MT1-MMP mAb was obtained with 84% immunoreactivity to MT1-MMP and more than 92% radiochemical purity. MT1-MMP was highly expressed in all malignant cells. Tumor radioactivity increased with time after administration and reached 3 to 5 times higher values at 24 h post-injection than those at 1 h. Other organs, including the stomach, showed decreasing values over time. Tumor to blood ratios increased with time and reached more than 1.3 at 48 h. The effective dose was <5.0 muSv/MBq. The results suggest that (99m)Tc-anti-MT1-MMP mAb is a promising probe for future diagnosis of breast tumors by in vivo nuclear medical imaging.
Similar articles
- Miniaturized antibodies for imaging membrane type-1 matrix metalloproteinase in cancers.
Kondo N, Temma T, Shimizu Y, Watanabe H, Higano K, Takagi Y, Ono M, Saji H. Kondo N, et al. Cancer Sci. 2013 Apr;104(4):495-501. doi: 10.1111/cas.12102. Epub 2013 Feb 17. Cancer Sci. 2013. PMID: 23305265 Free PMC article. - Development of membrane type-1 matrix metalloproteinase-specific activatable fluorescent probe for malignant tumor detection.
Shimizu Y, Temma T, Sano K, Ono M, Saji H. Shimizu Y, et al. Cancer Sci. 2011 Oct;102(10):1897-903. doi: 10.1111/j.1349-7006.2011.02020.x. Epub 2011 Jul 29. Cancer Sci. 2011. PMID: 21718387 - Radioimmunodetection of membrane type-1 matrix metalloproteinase relevant to tumor malignancy with a pre-targeting method.
Sano K, Temma T, Kuge Y, Kudo T, Kamihashi J, Zhao S, Saji H. Sano K, et al. Biol Pharm Bull. 2010;33(9):1589-95. doi: 10.1248/bpb.33.1589. Biol Pharm Bull. 2010. PMID: 20823579 - Imaging with radiolabelled anti-membrane type 1 matrix metalloproteinase (MT1-MMP) antibody: potentials for characterizing atherosclerotic plaques.
Kuge Y, Takai N, Ogawa Y, Temma T, Zhao Y, Nishigori K, Ishino S, Kamihashi J, Kiyono Y, Shiomi M, Saji H. Kuge Y, et al. Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2093-104. doi: 10.1007/s00259-010-1521-2. Epub 2010 Jul 13. Eur J Nucl Med Mol Imaging. 2010. PMID: 20625725 - Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas.
de Lucas AG, Schuhmacher AJ, Oteo M, Romero E, Cámara JA, de Martino A, Arroyo AG, Morcillo MÁ, Squatrito M, Martinez-Torrecuadrada JL, Mulero F. de Lucas AG, et al. PLoS One. 2016 Jul 27;11(7):e0158634. doi: 10.1371/journal.pone.0158634. eCollection 2016. PLoS One. 2016. PMID: 27462980 Free PMC article.
Cited by
- Tumor Imaging Using Radiolabeled Matrix Metalloproteinase-Activated Anthrax Proteins.
Elvina Xavier MA, Liu S, Bugge TH, Torres JB, Mosley M, Hopkins SL, Allen PD, Berridge G, Vendrell I, Fischer R, Kersemans V, Smart S, Leppla SH, Cornelissen B. Elvina Xavier MA, et al. J Nucl Med. 2019 Oct;60(10):1474-1482. doi: 10.2967/jnumed.119.226423. Epub 2019 Apr 6. J Nucl Med. 2019. PMID: 30954944 Free PMC article. - MT1-MMP as a PET Imaging Biomarker for Pancreas Cancer Management.
Morcillo MÁ, García de Lucas Á, Oteo M, Romero E, Magro N, Ibáñez M, Martínez A, Garaulet G, Arroyo AG, López-Casas PP, Hidalgo M, Mulero F, Martínez-Torrecuadrada J. Morcillo MÁ, et al. Contrast Media Mol Imaging. 2018 Aug 26;2018:8382148. doi: 10.1155/2018/8382148. eCollection 2018. Contrast Media Mol Imaging. 2018. PMID: 30224904 Free PMC article. - In vivo imaging of membrane type-1 matrix metalloproteinase with a novel activatable near-infrared fluorescence probe.
Shimizu Y, Temma T, Hara I, Makino A, Kondo N, Ozeki E, Ono M, Saji H. Shimizu Y, et al. Cancer Sci. 2014 Aug;105(8):1056-62. doi: 10.1111/cas.12457. Epub 2014 Jul 31. Cancer Sci. 2014. PMID: 24863849 Free PMC article. - Monitoring and Inhibiting MT1-MMP during Cancer Initiation and Progression.
Pahwa S, Stawikowski MJ, Fields GB. Pahwa S, et al. Cancers (Basel). 2014 Feb 17;6(1):416-35. doi: 10.3390/cancers6010416. Cancers (Basel). 2014. PMID: 24549119 Free PMC article. - Miniaturized antibodies for imaging membrane type-1 matrix metalloproteinase in cancers.
Kondo N, Temma T, Shimizu Y, Watanabe H, Higano K, Takagi Y, Ono M, Saji H. Kondo N, et al. Cancer Sci. 2013 Apr;104(4):495-501. doi: 10.1111/cas.12102. Epub 2013 Feb 17. Cancer Sci. 2013. PMID: 23305265 Free PMC article.